Resona Asset Management Co. Ltd. Reduces Stock Position in IQVIA Holdings Inc. $IQV

Resona Asset Management Co. Ltd. lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 6.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 52,882 shares of the medical research company’s stock after selling 3,352 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in IQVIA were worth $11,936,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in IQVIA by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after acquiring an additional 159,899 shares during the period. Alliancebernstein L.P. raised its position in IQVIA by 1.2% in the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after acquiring an additional 41,643 shares during the period. Boston Partners bought a new position in IQVIA in the third quarter worth approximately $676,698,000. Artisan Partners Limited Partnership raised its position in IQVIA by 4.9% in the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock worth $652,246,000 after acquiring an additional 161,085 shares during the period. Finally, Invesco Ltd. raised its position in IQVIA by 15.3% in the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after acquiring an additional 367,204 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price target on the stock. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, April 19th. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. UBS Group decreased their price target on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Finally, Jefferies Financial Group decreased their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Buy” and a consensus price target of $225.69.

IQVIA Stock Down 1.0%

Shares of IQV stock opened at $171.47 on Thursday. The company has a market capitalization of $28.62 billion, a price-to-earnings ratio of 21.25, a PEG ratio of 1.66 and a beta of 1.18. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company’s fifty day moving average price is $169.85 and its 200-day moving average price is $198.11. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period last year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has approved a stock repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.